Canakinumab + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia

Conditions

Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia

Trial Timeline

Apr 30, 2020 → Dec 22, 2020

NCT ID

NCT04362813

About Canakinumab + Placebo

Canakinumab + Placebo is a phase 3 stage product being developed by Novartis for Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT04362813. Target conditions include Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia.

What happened to similar drugs?

0 of 1 similar drugs in Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia were approved

Approved (0) Terminated (0) Active (1)

🔄Ruxolitinib + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05725343	Phase 3	Terminated	Feb 3, 2022	Sep 21, 2022	Lung Cancer
NCT04510493	Phase 3	Completed	Oct 23, 2020	Aug 17, 2021	Coronavirus Infection
NCT04362813	Phase 3	Completed	Apr 30, 2020	Dec 22, 2020	Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
NCT03447769	Phase 3	Terminated	Mar 16, 2018	Feb 7, 2023	Non-Small Cell Lung Cancer
NCT02059291	Phase 3	Completed	Jun 27, 2014	Jul 4, 2017	Hereditary Periodic Fevers
NCT01390350	Phase 2	Completed	Jul 1, 2011	May 1, 2018	Schnitzler Syndrome
NCT00889863	Phase 3	Completed	Jul 1, 2009	Sep 1, 2011	Systemic Juvenile Idiopathic Arthritis With Active Flare
NCT00886769	Phase 3	Terminated	Jul 1, 2009	Jan 1, 2011	Systemic Juvenile Idiopathic Arthritis
NCT00581945	Phase 1/2	Completed	Jan 1, 2007	May 1, 2010	Chronic Obstructive Pulmonary Disease
NCT00424346	Phase 2	Completed	Nov 1, 2006	Oct 1, 2009	Rheumatoid Arthritis

Competing Products

3 competing products in Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia

See all competitors

Product	Company	Stage	Hype Score
canakinumab	Novartis	Pre-clinical	26
Ruxolitinib + Placebo	Novartis	Phase 3	40
Itacitinib + Immune effector cell therapy + Placebo + Yescarta	Incyte	Phase 2	32